Nelfinavir: an update on its use in HIV infection (Q33897234)

29 July 2017

1 reference

title

Nelfinavir: an update on its use in HIV infection (English)

1 reference

29 July 2017

1 reference

A Bardsley-Elliot

1

1 reference

PubMed ID

10776836

29 July 2017

G L Plosker

series ordinal

2

1 reference

29 July 2017

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

59

1 reference

29 July 2017

3

1 reference

29 July 2017

581-620

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200059030-00014

29 July 2017

0 references

cites work

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00014

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00014

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

12 December 2020

Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

12 December 2020

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

12 December 2020

Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice

1 reference

12 December 2020

Nelfinavir. A review of its therapeutic efficacy in HIV infection

1 reference

12 December 2020

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

12 December 2020

Nelfinavir-induced urticaria and successful desensitization

1 reference

12 December 2020

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

1 reference

12 December 2020

Nelfinavir mesylate: a protease inhibitor

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Exacerbated Hyperglycemia Associated with Nelfinavir

1 reference

12 December 2020

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

1 reference

12 December 2020

A review of protease inhibitor-induced hyperglycemia.

1 reference

12 December 2020

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons

1 reference

12 December 2020

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

12 December 2020

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

12 December 2020

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

1 reference

12 December 2020

Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between nelfinavir and nevirapine.

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

12 December 2020

Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge

1 reference

12 December 2020

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

12 December 2020

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

12 December 2020

1 reference

12 December 2020

The HIV-1 protease as a therapeutic target for AIDS

1 reference

12 December 2020

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

12 December 2020

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

12 December 2020

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Nelfinavir associated with peripheral neuropathy in an HIV-infected patient

1 reference

12 December 2020

Dynamic correlation of apoptosis and immune activation during treatment of HIV infection

1 reference

12 December 2020

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Severe diabetes associated with protease inhibitor therapy

1 reference

12 December 2020

Nelfinavir, a new protease inhibitor: early clinical results

1 reference

12 December 2020

Indinavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

1 reference

12 December 2020

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study

1 reference

12 December 2020

Impact of drug resistance mutations on virologic response to salvage therapy

1 reference

12 December 2020

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

12 December 2020

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

12 December 2020

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

12 December 2020

Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy

1 reference

12 December 2020

Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease

1 reference

12 December 2020

Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Attaining higher goals in HIV treatment: the central importance of adherence

1 reference

12 December 2020

HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors

1 reference

12 December 2020

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

12 December 2020

The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.

1 reference

12 December 2020

Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

12 December 2020

Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype

1 reference

12 December 2020

Virological response to protease inhibitor therapy in an HIV clinic cohort.

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation

1 reference

12 December 2020

10.2165/00003495-200059030-00014

Identifiers

DOI

1 reference

PubMed ID

10776836

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10776836